COVID-19 May Reactivate Dormant Viruses
Overview
A longitudinal study found that nearly half of COVID-19 hospitalized patients had detectable reactivation of chronic viruses. The study does not confirm a causal link between viral reactivation and severe disease or long COVID.
Background
The reactivation of dormant viruses during acute COVID-19 illness raises important questions about the interplay between viral infections and disease severity.
Data Highlights
| Finding | Percentage |
|---|---|
| Epstein-Barr virus reactivation (days 1-8) | 24% |
| Human alphaherpesvirus 1 detection (days 19-23) | 43% (endotracheal aspirates), 15% (nasal samples) |
| Cytomegalovirus in peripheral blood | 8% |
| Chronic viral transcripts detected | 550 of 1,148 patients |
Key Findings
- Nearly 50% of hospitalized COVID-19 patients had reactivation of at least one chronic virus.
- Epstein-Barr virus reactivation was detected in 24% of patients during the first week.
- Human alphaherpesvirus 1 was found in 43% of patients with endotracheal aspirates around days 19-23.
- Cytomegalovirus was present in 8% of peripheral blood samples during the same period.
- Herpesvirus and Anelloviridae transcripts were linked to greater COVID-19 severity.
- Viral detection did not correlate with long COVID symptom groups.
Clinical Implications
Clinicians should remain aware of the potential for viral reactivation but should follow current guidelines that prioritize SARS-CoV-2-directed therapies.
Conclusion
This study provides data on the prevalence of chronic viral reactivation in COVID-19 patients.
Related Resources & Content
- Nature, 2026 -- Virus reactivation in acute and long COVID-19
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19
- MDSpire News — Medical Oddities: Something Viral is Lurking in the Dust
- Infection — Reappearance of COVID-19 Following Recovery: A Case Study from Italy
- the pathologist — Bat News: Pandemic Potential
- The ASCO Post — Could SARS–CoV-2 Be an Oncogenic Agent and Cancer Initiator?
- Medical Oddities: Something Viral is Lurking in the Dust
- Reappearance of COVID-19 Following Recovery: A Case Study from Italy
- Bat News: Pandemic Potential
- Virus reactivation in acute and long COVID-19 | Nature
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19
- Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Sepsis-Associated Acute Respiratory Failure: A Phase 3 Randomized Placebo-Controlled Trial | American Journal of Respiratory and Critical Care Medicine | Oxford Academic
Based on findings from:
COVID-19 May Reactivate Dormant Viruses
The Pathologist, 2026.
https://www.thepathologist.com/issues/2026/articles/september/covid-19-may-reactivate-dormant-viruses/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.